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Abstract Huntington’s disease (HD) is a debilitating
neurodegenerative condition with significant burdens on
both patient and healthcare costs. Despite extensive
research, treatment options for patients with this condition
remain limited. Aberrant post-translational modification
(PTM) of proteins is emerging as an important element in
the pathogenesis of HD. These PTMs include acetylation,
phosphorylation, methylation, sumoylation and ubiquitina-
tion. Several families of proteins are involved with the
regulation of these PTMs. In this review, I discuss the
current evidence linking aberrant PTMs and/or aberrant
regulation of the cellular machinery regulating these PTMs
to HD pathogenesis. Finally, I discuss the evidence
suggesting that pharmacologically targeting one of these
protein families the histone deacetylases may be of
potential therapeutic benefit in the treatment of HD.
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Histone post-translational modifications
Introduction
Huntington’s disease (HD) is an autosomal dominant, late-
onset neurodegenerative disease characterized by cognitive
dysfunction, psychiatric symptoms and movement disorders
(Walker 2007). The disease is caused by an expansion of a
polyglutamine repeat within the amino terminus of the
predominantly cytosolic protein huntingtin (Htt; DiFiglia et
al. 1995; Group 1993). The expanded repeat region results
in nuclear translocation and aggregation of huntingtin and
has been implicated as the causative event in the pathogen-
esis of this disease (Klement et al. 1998; Sieradzan et al.
1999; Saudou et al. 1998).
Epigenetic regulation of gene expression involves stable
and heritable changes in gene expression which are not due
to changes in the primary DNA sequence. Current known
epigenetic mechanisms involve the following: DNA CpG
methylation, histone post-translational modifications
(PTMs), gene imprinting and non-coding RNA.
The ‘histone code’ is a well-established hypothesis
describing the idea that specific patterns of post-translational
modifications to histones act like a molecular ‘code’
recognised and used by non-histone proteins to regulate
specific chromatin functions. These modifications include
acetylation, methylation, phosphorylation, sumoylation and
ubiquitination, and various families of proteins have been
identifiedwhich functiontoplace orremovethese PTMs. The
best studied of these families are the K-acetyltransferases
(KATs),histone deacetylases(HDACs),K-methyltransferases
(KMTs) and K-demethylases (KDMs; Allis et al. 2007).
KATs (formerly known as either histone acetyltransferases
or lysine acetyltransferases; Allis et al. 2007)f u n c t i o nt o
covalently add acetyl groups to lysine residues on proteins.
Likewise, KMTs add methyl groups to lysine residues either
as mono-, di- or tri-methylation (Albert and Helin 2010),
whilst HDACs and KDMs remove these respective mod-
ifications (Allis et al. 2007). Whilst many of these PTMs
were originally identified on histones, it is becoming
increasingly evident that these PTMs play important roles
on many proteins leading to the notion of a ‘protein code’
exemplified by the proteins p53 (Sims and Reinberg 2008)
and nuclear factor kappa-B (NFkB; Calao et al. 2008).
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DOI 10.1007/s13148-011-0025-7Indeed, the Htt protein has been found to be extensively
modified by several PTMs including acetylation, sumoy-
lation, ubiquitination and phosphorylation (Table 1).
Focusing on Huntington’s disease (HD), I discuss the
current knowledge supporting the notion that the proteins
involved with histone/protein PTMs play important regu-
latory roles in the pathogenesis of this disease and discuss
whether inhibitors which target HDACs may have poten-
tial for use in targeting this disease.
Linking histone PTM machinery with HD
Lysine acetylation/deacetylation in HD
Much evidence has emerged directly linking KATs and
HDACs with HD (Table 2). For instance, mutant Htt
protein was quickly shown to form a complex with the
lysine acetyltransferases KAT3A (CBP) and KAT2B
(P/CAF; Nucifora et al. 2001; Steffan et al. 2001, 2000;
Kazantsev et al. 1999). Once this complex is established,
it in turn can then interact with p53 and repress
transcription of p21WAF1/CIP1 and MDR-1 (Steffan et
al. 2000). Evidence has also accumulated linking func-
tional associations between huntingtin and HDACs.
Huntingtin associates with the co-repressors mSin3a and
N-CoR which recruit HDACs to repress transcription
(Boutell et al. 1999; Steffan et al. 2000). Indeed in the
absence or presence of ligand, mutant huntingtin has been
shown to both increase nuclear co-repressor function and
enhance ligand-dependent nuclear hormone receptor acti-
vation (Yohrling et al. 2003).
The potential importance of histone deacetylases in HD
was highlighted in a Caenorhabditis elegans model of HD,
where specifically targeting HDACs reduced neurodegen-
eration (Bates et al. 2006). Defects in microtubule-based
transport have been shown to contribute to neuronal
toxicity in Huntington’s disease (Muchowski et al. 2002;
Hoffner et al. 2002; Trushina et al. 2003). HDAC6 has been
shown to be a microtubule-associated deacetylase (Hubbert
et al. 2002). Levels of acetylated tubulin have been found to
be reduced in the brains of Huntington’s patients, and in
vitro cell studies targeting HDAC6 resulted in the allevia-
tion of transport- and release-defect phenotypes in the cell
models via increased acetylation at lysine 40 of alpha-
tubulin (Dompierre et al. 2007).
Table 1 Sites in the Htt protein which undergo PTMs
Acetylation
K6 (Aiken et al. 2009)
Palmitoylation
C214 (Yanai et al. 2006)
Phosphorylation
T3 (Aiken et al. 2009)
S13 (Aiken et al. 2009; Thompson et al. 2009; Gu et al. 2009)
S16 (Aiken et al. 2009; Gu et al. 2009)
T407 (Dephoure et al. 2008)
S413 (Dephoure et al. 2008)
S421 (Colin et al. 2008; Humbert et al. 2002; Pardo et al. 2006;
Rangone et al. 2004; Warby et al. 2009; Zala et al. 2008)
S434 (Luo et al. 2005)
S533 (Schilling et al. 2006)
S535 (Schilling et al. 2006)
S536 (Schilling et al. 2006)
S1181 (Anne et al. 2007; Daub et al. 2008; Schilling et al. 2006)
S1872 (Daub et al. 2008; Dephoure et al. 2008)
S1876 (Dephoure et al. 2008; Xia et al. 2008)
S1201 (Anne et al. 2007; Brill et al. 2009; Daub et al. 2008;
Schilling et al. 2006)
S2076 (Schilling et al. 2006)
S2653 (Schilling et al. 2006)
S2657 (Schilling et al. 2006)
T2940 (Dephoure et al. 2008)
Sumoylation
K6, K9, K15 (Steffan et al. 2004)
Ubiquitination
K6, K9, K15 (Steffan et al. 2004)
The table was generated through the use of SysPTM (http://lifecenter.
sgst.cn/SysPTM; Li et al. 2009), PhosphoSitePlus® (http://www.
phosphosite.org/) and literature searches
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258 Clin Epigenet (2011) 2:257–277Critically, acetylation of Htt has been shown to target the
mutant protein to autophagosomes for degradation. In-
creased acetylation at a single lysine (K444) was recently
shown to facilitate the trafficking of mutant Htt into
autophagosomes and significantly improved the clearance
of the mutant protein by macroautophagy. In experimental
models, this reversed the toxic effects of mutant huntingtin
in primary striatal and cortical neurons and in a transgenic
C. elegans model of HD. If the protein was altered to be
resistant to acetylation, this resulted in dramatic aggregation
leading to neurodegeneration in cultured neurons and in
mouse brain (Jeong et al. 2009). Overexpression of
I-kappa-B kinase (IKK)β, an important regulator of the
NFkB transcription factor (Mankan et al. 2009), results in
acetylation of Htt at K9 and phosphorylation at S13,
leading to elevated nuclear translocation of Htt protein
(Thompson et al. 2009).
Lysine ubiquitination/sumoylation in HD
The mutant huntingtin protein has been shown to alter
levels of histone monoubiquitination, through an altered
ability to interact with Bmi-1, a component of the hPRC1L
E3 ubiquitin ligase complex, resulting in increased levels of
monoubiquitinated histone H2A (uH2A) and aberrant gene
expression (Kim et al. 2008). When gene expression
patterns were examined in the brains of transgenic R6/2
mice, promoters of genes which were repressed were found
to have increased levels of ubiquitinated H2A (uH2A) and
decreased levels of ubiquitinated H2B (uH2B), whilst
active promoters had the opposite (increased u2H2B and
decreased uH2A). Furthermore, targeting histone ubiquitin
in cell line models demonstrated that reducing uH2A led to
the reactivation of repressed genes associated with
a reduction in levels of histone lysine 9 methylation
(H3K9me)2 and trimethylated histone H3 lysine 9
(H3K9me3) at the reactivated promoters. Conversely
reductions of uH2B induced transcriptional repression
through inhibition of monomethylation at histone H3 lysine
4 (Fig. 1; Kim et al. 2008).
Modification of proteins with polyubiquitin chains regu-
lates many essential cellular processes including protein
degradation, cell cycle, transcription, DNA repair and
membrane trafficking. As discussed in previous sections, in
Huntington’s disease, monoubiquitination of histones results
in aberrant gene expression patterns. Evidence now links Htt
ubiquitination to HD pathogenesis. Aggregation-prone pro-
teins such as Htt have been suggested to overwhelm and
impair the ubiquitin/proteasome system (UPS) in polyglut-
amine (polyQ) disorders. One study found that accumulation
of ubiquitin conjugates in a HD disease model occurred
without impairment of the ubiquitin/proteasome system
(Maynard et al. 2009). However, two other studies have
shown that UPS dysfunction is a consistent feature of HD
pathology with impaired UPS in the synapses of HD mice
(Wang et al. 2008) and with polyubiquitination chains
occurring on Htt lysines 11, 48 and 63 (Bennett et al. 2007).
Htt has also been shown to be either ubiquitinated or
sumoylated at the same lysine residues (K6, K9 and K15).
Sumoylation stabilizes Htt and reduces its ability to form
aggregates, whilst enhancing transcriptional repression, and
exacerbated neurodegeneration in a drosophila model of
HD, whereas ubiquitination of these residues abrogated
neurodegeneration in the same model (Steffan et al. 2004).
More recently, a novel striatal protein, Rhes, has been
shown to associate with Htt. This protein has now been
shown to induce Htt sumoylation leading to neuronal
cytotoxicity (Subramaniam et al. 2009).
Lysine methylation in HD
H3K9me3 levelsare elevated in bothHD patientsand in R6/2
transgenic mice and are associated with increased amounts of
KMT1E (also known as known as ESET/SETDB1; Table 2;
Ryu et al. 2006). This enzyme methylates H3K9me3, and
whilst this is generally considered to be a mark of
transcriptional repression and heterochromatinization
(Hublitz et al. 2009), it has also been associated with active
transcription genes particularly in disease states such as
cancer (Wiencke et al. 2008). Within the neuronal setting,
monoallelic deletion of the lysine acetyltransferase KAT3A
(CBP) results in the induction of KMT1E (ESET) with
concomitant increased H3K9me3 in neurons (Lee et al.
2008), suggesting that KAT3A (CBP) may be a regulator of
KMT1E (ESET) gene expression and raising the notion that
increased KAT activity may be a way of targeting the
aberrant KMT1E (ESET)-mediated H3K9me3 levels in
patients with HD (Table 2).
Deubiquitination of H2B in yeast initiates the recruit-
ment of a complex containing the kinase Ctk1. This kinase
subsequently phosphorylates the RNA polymerase II (Pol
II) C-terminal domain, an event essential for the subsequent
recruitment of KMT3A (Set2/HYBP) lysine methyltrans-
ferase (Wyce et al. 2007). One of the functions of this KMT
is to regulate RNA Pol II elongation (Krogan et al. 2003;
Wyce et al. 2007; Li et al. 2003; Xiao et al. 2003; Schaft et
al. 2003; Morris et al. 2005). However, KMT3A (Set2/
HYPB)-mediated H3K36 methylation also functions to
recruit histone deacetylase complexes to restore normal
chromatin structure in the wake of elongating Pol II (Keogh
et al. 2005; Lee and Shilatifard 2007). Indeed KMT3A
would appear to be essential for all H3K36me3 during gene
induction both in vitro (Edmunds et al. 2008) and in vivo
(Yuan et al. 2009). The human homologue of this KMTwas
originally described as huntingtin interacting protein B
(HYPB; Sun et al. 2005a), suggesting that KMT3A (Set2/
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tional regulation and play critical roles in the pathogenesis
of HD (Sun et al. 2005a).
The Htt protein has now been shown to associate with
the Polycomb repressive complex 2 (Seong et al. 2010).
EZH2 (also known as KMT6) is the catalytic subunit of
Polycomb repressive complex 2 (PRC2) and is a highly
conserved histone methyltransferase that targets lysine-27
of histone H3 (Cao et al. 2002; Kuzmichev et al. 2002).
Mutant Htt was found to be associated with reduced histone
H3K27 tri-methylation, whilst recombinant wild-type Htt
was found to significantly enhance the histone H3K27 tri-
methylase activity of reconstituted PRC2 in vitro (Seong et
al. 2010). Whilst there is currently little evidence demon-
strating aberrant KDM activity in the pathogenesis of neuro-
degeneration, it has recently been shown that a neurospecific
splice variant of KDM1 (LSD1) exists which is dynamically
regulated throughout cortical development and functions to
modulate neurite morphogenesis (Zibetti et al. 2010).
Lysine phosphorylation
In the R6/2 transgenic mouse model of HD, nuclear
activation of the mitogen-activated protein kinase/extracel-
lular regulated kinase (ERK) failed to induce histone H3
phosphorylation, an expected response of nuclear ERK
activation. It was subsequently found that this was due to a
decrease in expression of mitogen- and stress-activated
kinase-1 (MSK-1), a kinase downstream ERK, critically
involved in H3 phosphorylation, a finding subsequently
confirmed in the striatal neurons and postmortem brains of
HD patients and suggesting that aberrant MSK-1 expres-
sion is involved with the transcriptional dysregulation and
striatal degeneration in patients with HD (Roze et al. 2008).
Recently, it has been shown that phosphorylation of
mutant Htt by the inflammatory kinase complex (IKK)
regulates additional post-translational modifications, in-
cluding Htt ubiquitination, sumoylation and acetylation,
resulting in increased Htt nuclear localization, cleavage and
clearance mediated by lysosomal-associated membrane
protein 2A and Hsc70 (Thompson et al. 2009). In
particular, phosphorylation of serines (S6/S13) promotes
the degradation of Htt by both the proteasome and
lysosomes. These modifications, however, also result in
enhanced translocation of Htt to the nucleus, which may
result in both aberrant gene expression and enhanced
neurodegeneration over time (Thompson et al. 2009).
However, phosphorylation of Htt on serine 421 (S421)
can reduce nuclear accumulation of huntingtin fragments by
(a) reducing huntingtin cleavage by caspase-6, (b) affecting
the levels of full-length huntingtin and (c) altering its
nuclear localization (Warby et al. 2009). Phosphorylation of
serine 434 (S434) by CDK5 has also been found to reduce
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Fig. 1 Overview of epigenetic regulators affecting gene expression in Huntington’s disease. p phosphorylation, u ubiquitination, s sumoylation,
ac acetylation, me methylation, ups ubiquitin/proteasome system, KAT K-acetyltransferase, KMT K-methyltransferase
260 Clin Epigenet (2011) 2:257–277et al. 2005). Additionally, phosphorylation of Htt may also
directly regulate Htt function, as phosphorylation at S431
restores its axonal transport (Zala et al. 2008), whilst
phosphorylation of Htt at S431 by Akt is critical to
controlling the direction of vesicle movement in neurons
(Colin et al. 2008). Furthermore, phosphorylation at Htt
serines S1181 and S1201 are critical to HD pathogenesis. If
phosphorylation is absent, this confers toxic properties to
wild-type huntingtin in a p53-dependent manner in striatal
neurons and accelerates neuronal death induced by DNA
damage, whilst if present they prevent this toxicity (Anne et
al. 2007).
Consequences of mutant Htt and aberrant PTMs in HD
Clear links between aberrant histone post-translational
modifications and disease pathogenesis have been demon-
strated, and one of the most extensively studied of these
modifications is histone acetylation. Indeed, acetylation of
histones in brain neuronal fractions was observed as early
as 1975 (Sarkander et al. 1975), and it has now been
demonstrated that HDACs play important roles in both
neuron differentiation (Liu et al. 2008), expression of
neuron-specific genes (Lakowski et al. 2006) and the
regulation of diverse cues such as maternal grooming
(Weaver et al. 2004) and addiction (Renthal et al. 2007).
Class II and class III histone deacetylases play pivotal roles
in both neuronal proliferation and differentiation (Horio et
al. 2003; Kyrylenko et al. 2003; Ajamian et al. 2003;
Hoshino et al. 2003). SIRT1 has also been shown to protect
primary cultures of cerebral granule neurons from FOXO-
induced cell death (Brunet et al. 2004).
Because Htt has been shown to associate with the
cellular machinery responsible for regulating the histone
code, it has been postulated that this may lead to aberrant
gene expression in patients suffering from HD. Three
potential mechanisms as to how this might occur have
been identified: (1) mislocalization of KATs. The associa-
tion of mutant Htt and KATs affects the nuclear localization
of KATs in neuronal cells into intranuclear inclusions
(Steffan et al. 2000;N u c i f o r ae ta l .2001). As such
depletion of this KAT from its normal localization by
this aggregation may result in aberrant transcriptional
control; (2) direct inhibition of KATs. Cell-free assays
have shown that mutant huntingtin protein can directly
inhibit KAT activity (Steffan et al. 2001), indicating a
direct interference mechanism; and (3) enhanced degrada-
tion of KATs. A cell line of mutant Htt protein found that
this was associated with enhanced degradation of KAT3A
(CBP) indicating that the mutant Htt may actively
eliminate this KAT from the affected neurons (Jiang et
al. 2003, 2006;C o n ge ta l .2005).
As a consequence, gene expression is altered in patients
with HD. Microarray gene profiling studies on HD patients
have identified a subset of upregulated mRNAs that can
distinguish between controls, presymptomatic HD mutation
carriers and symptomatic HD patients (Borovecki et al.
2005). Furthermore, in a microarray analysis of a yeast
model of expanded polyglutamine tracts, the changes in
gene expression profiles closely matched those of yeast
strains deleted for components of the Spt/Ada/Gcn5
acetyltransferase lysine acetyltransferase complex (Hughes
et al. 2001). Additional evidence for aberrant gene
expression comes from transgenic mice models of HD.
For example, histone H3 is hypo-acetylated at the pro-
moters of downregulated genes in R6/2 transgenic mice
(Sadri-Vakili et al. 2007; Stack et al. 2007), whilst in
transgenic N171-82Q (82Q) and R6/2 HD mice, the
reduced histone 3 lysine 9 acetylation is concomitant with
increased H3K9me and associated gene expression changes
(Stack et al. 2007). In the sections below, I shall describe in
more detail some of the mechanisms involving histone
modifying complexes by which aberrant gene expression
occurs in HD.
PGC-1 alpha
It is well established that PPAR gamma co-activator 1 alpha
(PGC-1alpha) functions as a transcriptional co-activator/co-
repressor through associations with both KATs and HDACs
to regulate expression of genes involved with mitochondrial
energy and metabolism (Lawless et al. 2009c). PGC-1alpha
has also been linked to the development and pathogenesis
of HD. Small nucleotide polymorphisms (SNPs) studies
have identified particular SNPs within intron-2 of the PGC-
1alpha gene that are associated with a delay in age at onset
of motor symptoms in patients with Huntington’s disease
(Taherzadeh-Fard et al. 2009; Weydt et al. 2009). Another
SNP study has identified a SNP (rs2970870) within the
promoter associated with earlier onset of HD in the
homozygous state and a SNP within the transcribed region
(rs7665116) associated with a delayed onset (Che et al.
2011). Significantly reduced levels of PGC-1alpha occur in
the muscle of HD patients and HD transgenic mice, whilst
‘knockdown’ of mutant Htt in myoblasts leads to increased
PGC-1alpha (Chaturvedi et al. 2009). Reduced expression
of PGC-1alpha target genes also is found in the striatum of
HD patients and mouse models (Weydt et al. 2006). When
PGC-1alpha knockout mice were crossbred with HD
knockin mice, increased neurodegeneration of striatal
neurons and motor abnormalities was found to occur.
Ectopic expression of PGC-1alpha was able to partially
ablate the toxic effects of mutant huntingtin in cultured
striatal neurons, whilst lentiviral-mediated PGC-1alpha
provided neuroprotection in the striatum of transgenic HD
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transplanted into the striatum of R6/2 HD mice, increased
survival, attenuation of striatal neuron loss and reductions in
levels of huntingtin aggregates were observed which corre-
lated with elevated levels of PGC-1alpha (Lee et al. 2009).
HDAC/REST complexes
One of the best established mechanisms in the regulation of
neuronal development relates to genes which are regulated
by the repressor element-1 (RE1)/neuronal restrictive
silencer element. A specific protein called repressor
element silencing transcription factor (REST), also known
as neuron-restrictive silencing factor (NRSF), binds to this
element and prevents the expression of these genes in non-
neuronal cells (Seth and Majzoub 2001; Belyaev et al.
2004). REST is a critical protein in development (Chen et
al. 1998) and is essential for proper neuronal differentiation
and maturation (Paquette et al. 2000;A b r a j a n oe ta l .2009a, b).
A functional link to aberrant REST activity and selective loss
of neurons has been shown in a study of Down’s syndrome
(Bahn et al. 2002). In addition, a Nurr1/CoREST pathway in
microglia and astrocytes has been shown to protect neurons
from inflammation-induced death in Parkinson’sd i s e a s e
(Saijo et al. 2009).
REST contains two distinct repressor domains, one
located at the N terminus and the other at the C terminus
of the protein (Thiel et al. 1998; Tapia-Ramirez et al. 1997).
Two distinct neuronal repressor complexes have now been
isolated containing both REST and HDACs. The first of
these complexes involves direct interactions with mSin3A/B
at the N terminus which then recruits HDACs to repress gene
expression (Grimes et al. 2000; Huang et al. 1999;N a r u s ee t
al. 1999;R o o p r ae ta l .2000). The C-terminal repression
domain associates with a novel protein called CoREST
(Andres et al. 1999). This protein also interacts with HDACs
through its SANT domain and has been shown to be
essential for repression (You et al. 2001) and in particular
actively represses genes essential for neuronal phenotype
(Ballas et al. 2005). The ATP-dependent remodelling
complex SWI/SNF also plays a role in REST-mediated
neuronal gene regulation as CoREST recruits several SWI/
SNF members, indicating that active chromatin remodelling
is an element in REST-mediated repression (Battaglioli et al.
2002; Watanabe et al. 2006). CoREST complexes have also
been shown to contain lysine demethylases, and recently, a
KDM1–CoREST–CtBP co-repressor complex was shown to
be required for late cell-lineage determination and differen-
tiation during pituitary organogenesis (Wang et al. 2007a).
In HD, levels of a microRNA miR-9/miR-9A are
downregulated. This microRNA has been identified as a
critical regulator of REST/NRSF (Packer et al. 2008), and
loss of this miRNA results in increased levels of nuclear
REST/NRSF activity (Bithell et al. 2009). As REST/NRSF
has been shown to associate with Htt (Zuccato et al. 2003),
KMTs and HDACs (Gray 2009), this may result in aberrant
regulation of gene expression. Indeed, in this context,
REST/NRSF has been shown to regulate several miRNAs
(Conaco et al. 2006; Wu and Xie 2006). Because nuclear
REST/NRSF activity is increased in HD patients as a
consequence of loss of miR-9/miR-9A, this results in the
further loss of expression of a series of miRNAs regulated
by REST/NRSF in HD patients (Bithell et al. 2009).
For instance, a novel non-coding RNA human acceler-
ated region 1, specifically transcribed in the nervous
system, is regulated by REST/NRSF and has been shown
to be downregulated in HD patients (Johnson et al. 2010).
Expression of another miRNA, mIR-22, has been shown to
be downregulated in two transgenic mouse models of HD
(YAC128 and R6/2; Lee et al. 2011). This miRNA has
recently been shown to be involved with the regulation of
HDAC4 in hepatocellular carcinoma, in that cancers with
low levels of this miRNA had elevated levels of HDAC4
(Zhang et al. 2010). It must be noted that in the R6/2 HD
mouse model, decreased levels of HDAC4 protein were
observed in the cortex (Quinti et al. 2010).
Motor neuron genes modulated by HDACs
In addition to RE1/NSRE-directed repression of specific
genes, motor neurons also express unique combinations of
LIM-type homeodomain factors. These function to define
motor column identity by regulating particular gene
expression profiles (Sharma et al. 1998). LIM homeodo-
main transcription factors have been shown to be regulated
through a complex containing HDACs (Bach et al. 1999),
and as such motor neuron pathfinding may be guided
through an HDAC-directed process.
HDACs within the neuronal setting of HD
E2F, HDACs and neuronal survival mechanisms
An essential feature for neuronal survival has also been
linked to constitutive repression of E2F1 transcriptional
activity through HDAC proteins (Boutillier et al. 2002).
Elevated levels of E2F1 lead to neuronal apoptosis
(Konishi and Bonni 2003;H o ue ta l .2000) and enhanced
immune cell proliferation (Wu et al. 2001), factors that
could be deleterious in HD. Indeed, elevated levels of E2F
have been found in the brains of patients suffering from
HD (Pelegri et al. 2008). Subsequently, we demonstrated
that HDAC inhibitors reduce levels of E2F class I proteins
in vivo (Camelo et al. 2005), data which have been
recapitulated by others in vitro (Suzuki et al. 2000;S a i de t
262 Clin Epigenet (2011) 2:257–277al. 2001). These observations may therefore help to
explain why HDAC inhibitors block immune cell prolif-
eration (Dangond et al. 1998) and enhance neuronal
survival (Ryu et al. 2003).
HDACs play important roles in stem cell neuronal
differentiation
Increased neurogenesis has been observed in primary HD
patient material (Curtis et al. 2005), and mutant Htt has been
demonstrated to stimulate neuronal differentiation of embry-
onic and neural stem cells (Lorincz and Zawistowski 2009).
HDACs play important roles in neuronal stem cell (NSC)
differentiation. When Flag-tagged HDACs with reduced
enzymatic activity were used within a ‘dominant negative’
setting in stem cell lines, Howard and colleagues found that
mutant HDAC1 reduced neuron differentiation by 50%
(Humphrey et al. 2007). During murine development,
HDAC1 is expressed in neural stem cells/progenitors and
glia, whereas HDAC2 is found in neural progenitors and is
upregulated in post-mitotic neuroblasts and neurons, but not
in fully differentiated glia (MacDonald and Roskams 2008).
Using mice lacking HDAC1 or HDAC2, Olson and
colleagues demonstrate that these deacetylases do not have
an overt phenotype in neuronal progenitors. However, once
neuron development is initiated, these mice develop severe
hippocampal abnormalities, absence of cerebellar foliation,
disorganization of cortical neurons and lethality by postnatal
day 7, attributed to a failure of neuronal precursors to
differentiate into mature neurons and excessive cell death
(Montgomery et al. 2009). Prozorovski et al. (2008)h a v e
also linked the SIRT1 HDAC to differentiate neural
progenitor cells. A direct role for histone deacetylases in
the regulation of neural stem cell proliferation has been
shown where the orphan nuclear receptor TLX, a critical
regulator of stem cell proliferation, was found to associate
with HDAC3 and HDAC5. Inhibition of HDAC activity or
knockdown of HDAC expression led to marked induction of
TLX target gene expression and dramatically reduced neural
stem cell proliferation (Sun et al. 2007).
In vitro studies have also been shown to differentiate
neuronal precursor cells. Trichostatin A (TSA) treatment
of embryonic mouse NSCs increased neuronal differen-
tiation of the NSCs and decreased astrocyte differentia-
tion (Balasubramaniyan et al. 2006), whilst embryonic
stem cells can also be induced to differentiate into neurons
following inhibition of histone deacetylases (Yao et al.
2010). Furthermore, valproic acid has also been shown to
promote neuronal differentiation by inducing proneural
factors such as Ngn1, Math1 and p15 in association with
H4 acetylation at their promoters indicating that the
mechanism involved concerns inhibition of HDACs (Yu
et al. 2009).
Inhibition of histone deacetylases in lineage-committed
oligodendrocyte precursor cells activity acted as a priming
event in the induction of developmental plasticity (Lyssiotis
et al. 2007). A similar study examining the ability of
oligodendrocyte progenitors to acquire the identity of
myelin-expressing cells or choose alternative fates found
that the activity of histone deacetylases was critical to these
processes (Liu et al. 2007), and the transcription factor Yin
Yang 1 was shown to be a critical regulator of oligoden-
drocyte progenitor differentiation, acting as a lineage-
specific repressor of transcriptional inhibitors of myelin
gene expression (Tcf4 and Id4), through the recruitment of
histone deacetylase-1 to their promoters during oligoden-
drocyte differentiation (He et al. 2007).
REST is also critically involved with neural stem cell
differentiation. Activation of REST is sufficient to cause
neuronal differentiation (Su et al. 2004). REST complexes
are able to both silence and repress neuronal genes in
embryonic neural stem cells through the creation of
chromatin environments that contain both repressive and
active local epigenetic signatures (Greenway et al. 2007;
Sun et al. 2005b; Ballas et al. 2005). Neurons treated with a
combination of HDAC and transcription inhibitors display
an acetylation and transcription-dependent increase in
neural outgrowth, associated with KAT3A/KAt3B and
KAT2B-dependent p53 acetylation (Gaub et al. 2010).
HDACs, ER stress and pro-inflammatory pathways
in HD
Inflammation is a critical element associated with cancer
(Grivennikov et al. 2010), diabetes (Lawless et al. 2009b),
but also is increasingly linked to neurodegenerative disease
(Esiri 2007). Endoplasmic reticulum (ER) stress is another
cellular event which has also been implicated as a critical
component in all these conditions (Lawless et al. 2009a).
HDACs have been shown to be critical regulators of many
important cellular processes, and evidence is emerging
linking these enzymes in the regulation of inflammation
and ER stress responses. Whilst HD is not primarily
considered to be a pro-inflammatory disease as mouse
models of HD show little evidence for the involvement of
inflammation (Schwab et al. 2010), nevertheless it is well
established that one central mediator of inflammation,
NFkB, plays some role in HD pathogenesis. Over the
sections below, I shall link HDACs to both of these
important pathways within the context of HD.
HATs/HDACs, NFkB and HD
NFkB is a key mediator of inflammatory cascades, playing
important roles in regulating NFkB activation (Lawless et
Clin Epigenet (2011) 2:257–277 263al. 2009a; Mankan et al. 2009). NFkB typically consists of
a heterodimeric protein comprised of a p50 and a p65
(RelA) subunit. Initial studies identified lysine acetyltrans-
ferases KAT3A and KAT3B as key coactivators in
regulating NFkB-driven gene expression (Gerritsen et al.
1997; Perkins et al. 1997; Wadgaonkar et al. 1999). A
further lysine acetyltransferase KAT13A was also found to
potentiate NFkB transactivation through interactions with
p50 (Sirianni et al. 1998). It was then shown that the RelA/
p65 subunit can associate with HDACs 1–3 to repress
expression of NFkB-regulated genes as well as to control
the induced level of expression of these genes (Ashburner
et al. 2001;H o b e r ge ta l .2004, 2006). The histone
deacetylase SIRT1 also regulates NFkB transactivation by
deacetylating a critical lysine at position 310 of the RelA/
p65 subunit thereby inhibiting transcription (Yeung et al.
2004). A critical regulator of NFkB activation is IKKα.
NFkB transcription requires IKKα to phosphorylate silenc-
ing mediator for retinoic acid and thyroid hormone receptor
which in turn stimulates the exchange of co-repressor for
co-activator complexes. In the initial stages of NFkB
activation, the phosphorylation event causes HDAC3 to
be displaced from RelA/p65, allowing KAT3B to acetylate
RelA/p65 (Hoberg et al. 2004, 2006). IL-6 and IL-8 are
pro-inflammatory cytokines associated with responses to
NFkB activation (Esposito et al. 2003; Dandona et al.
2004a, b), and NFkB utilises the lysine acetyltransferase
activity of KAT3A/KAT3B to stimulate the transcription of
these genes (Vanden Berghe et al. 1999).
The protein Daxx regulates NFkB activation by binding
to a region which includes the major sites of acetylation
mediated by KAT3A/KAT3B (Park et al. 2007). However,
Daxx also directly associates with HDAC2 (Hollenbach et
al. 2002) and so may represent a mechanism by which
KATs and HDACs compete for critical lysines on NFkB
subunits. In this regard, small ubiquitin-like modifier
modification of KAT3A negatively modulates its transcrip-
tional activity by recruiting a Daxx complex which contains
HDAC2 (Kuo et al. 2005)
It is well established that inflammation is also a central
element in HD. Elevated NFkB activity has been found in
cultured cells expressing mutant Htt and striatal cells from
HD transgenic mice (Khoshnan et al. 2004). Furthermore,
several family members of the IKK proteins have been
shown to be functionally involved in HD. The IKK proteins
are critical regulators of NFkB. Indeed in the study
demonstrating activation of NFkB, it was found that mutant
Htt associated with and activated IKKγ (Khoshnan et al.
2004). Additional studies have shown that both IKKα and
IKKβ are involved in the proteolysis of Htt in response to
external cues such as DNA damage (Khoshnan et al. 2009).
IKK has also been shown to phosphorylate huntingtin
which targets it for degradation by the proteasome and
lysosome (Thompson et al. 2009). Critically once phos-
phorylated, IKK regulates additional post-translational mod-
ifications, of Htt including ubiquitination, sumoylation and
acetylation. Furthermore, this subsequently enhances Htt
nuclear localization, cleavage and clearance mediated by
lysosomal-associated membrane protein 2A and Hsc70. The
authors propose that IKK activates mutant Htt clearance until
an age-related loss of proteasome/lysosome function pro-
motes accumulation of toxic post-translationally modified
mutant Htt (Thompson et al. 2009).
HATs/HDACs, ER stress and HD
Theabilityofacelltosense,responsetoandcircumventstress
isessentialformaintaininghomeostasis.Therearemanyways
in which stress, either endogenous or exogenous, can be
manifested in a cell; these include pathogenic infection,
chemical insult, genetic mutation, nutrient deprivation and
even normal differentiation. The process of mutant protein
folding isparticularlysensitive tosuchinsults.Assuchfor the
cellular compartments in which mutant proteins are processed
and folded, there are adaptive programmes that enable both
their detection and correction for more efficient processing
(Rutkowski and Kaufman 2004).
The ER is a large cellular organelle comprising a
network of interconnected, closed membrane-bound
vesicles. It is the site of synthesis, folding and modification
of secretory and cell-surface proteins and serves many
essential functions, including the production of the compo-
nents of cellular membranes, proteins, lipids and sterols
(Hebert and Molinari 2007). Only correctly folded proteins
are transported out of the ER whilst incompletely folded
proteins are retained in the organelle to complete the
folding process or to be targeted for destruction (Rapoport
2007). Due to the important roles of the ER, its proper
functioning is therefore essential to cellular homeostasis.
Various conditions can, however, interfere with the ER
function leading to situation known as ER stress. Stress is
the response of any system to perturbations of its normal
state. Thus, ER stress can arise from a disturbance in
protein folding which results in an accumulation of
unfolded or misfolded proteins within the organelle (Lai
et al. 2007). During such disturbances, in order to carry out
the correct folding of proteins, the ER has evolved as a
specialized protein folding machine with cellular mecha-
nisms that promote proper folding of aberrant protein, thus
preventing its aggregation. When ER homeostasis is altered
by misfolded proteins, the ER responds by inducing
specific genes and attempting to restore normal ER function
and maintain stability (Caruso and Chevet 2007). The four
elements of ER stress are (1) protein degradation, (2)
endoplasmic overload response (EOR), (3) unfolded protein
response (UPR) and (4) cellular death pathway. This four-
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organelles role in the onset of clinical manifestations. Two
ER stress-induced signal transduction pathways have been
described: the UPR (Ron and Walter 2007) and the EOR
(Pahl and Baeuerle 1997). These pathways once activated
attempt to adapt to the disturbance and re-establish normal
ER function (Xu et al. 2005). In the case of misfolded
proteins, this is known as ER-associated degradation
(ERAD), the process by which these misfolded proteins
are exported to the cytosol for degradation by proteasomes
(Vembar and Brodsky 2008). Excessive or prolonged ER
stress can overwhelm the cells ability to cope and elicits the
cell death programme or apoptosis (Rao et al. 2004).
Evidence linking KATs/HDACs to ER stress is not as well
established as that for inflammation, with most studies
utilising histone deacetylase inhibitors. However, in a
recent study in hepatocytes on Mallory body (cytokeratin
aggresomes) formation, decreased histone acetyltransferase
and increased histone deacetylase activity were observed
(Bardag-Gorce et al. 2007). In a similar model of oxidative
stress-induced inclusion formation, treatment of cells with
4-phenylbutyrate (PB) was found to alleviate formation of
these inclusions (Hanada et al. 2007).
In terms of neurodegeneration, evidence is clearly emerging
linking ER stress to the pathogenesis of HD (Vidal et al. 2011).
The first indication that ER stress may be involved with
Huntington’s disease came from a study of aggresome-like
perinuclear inclusions generated using a huntingtin exon 1
truncated protein model in human 293 Tet-Off cells. In depth
analysis of these inclusion bodies demonstrated the presence
of markers of ER stress including the molecular chaperones
BiP/GRP78, Hsp70 and Hsp40 (Waelter et al. 2001).
Mutant huntingtin fragment proteins have now been
shown to elevate Bip (an ER chaperone), increase levels
of C/EBP homologous protein (CHOP; an ER stress-
induced regulator of cell death), increase the phosphor-
ylation of c-Jun-N-terminal kinase (a regulator of cell
death) and cleavage of caspase-3 and caspase-12 (medi-
ators of cell death; Reijonen et al. 2008). Inhibition of ER
stress using salubrinal counteracted both neuronal cell
death and protein aggregation by mutant Htt (Reijonen et
al. 2008). Functional analysis of Htt identified an
amphipathic alpha helical membrane-binding domain that
can reversibly target it to vesicles and the ER (Atwal and
Truant 2008; Atwal et al. 2007). Normal Htt is released
from these membranes in response to ER stress and
rapidly translocates into the nucleus. Once ER stress has
been alleviated, the Htt is capable of nuclear export and re-
association with the ER. However, this release is inhibited
when huntingtin contains the polyglutamine expansion
seen in Huntington’s disease. As a result, mutant hunting-
tin expressing cells have a perturbed ER and an increase in
autophagic vesicles, indicating that one of Htt’s functions
is to act as ER sentinel, potentially regulating autophagy in
response to ER stress (Atwal and Truant 2008; Atwal et al.
2007). Mutant Htt has also been shown to interact with
and abrogate the function of grp78, a critical ER
membrane-anchored ubiquitin ligase (E3) involved in
ERAD resulting in the induction of ER stress (Yang et
al. 2010). Furthermore, an additional protein, SCAMP5,
which functions to regulate the formation of expanded
polyglutamine repeat protein aggregates has been shown
to be induced in cultured striatal neurons by either ER
stress or mutant HTT (Noh et al. 2009). The heat shock
protein HspB8, when overexpressed, has been shown to
prevent mutant Htt aggregation through an autophagic
activity (Carra et al. 2005, 2008a, b, 2009).
In a presymptomatic knockin mouse model of HD, early
markers of disease regulator of ribosome synthesis Rrs1
and its interacting protein 3D3/lyric (also known as
metadherin and astrocyte elevated gene-1) were found to
be localised in the ER, are induced by ER stress and are
involved in the ER stress response in neuronal cells
(Carnemolla et al. 2009). Indeed, levels of Rrs1 mRNA
have been shown to be elevated in the brains of HD patients
(Fossale et al. 2002). Furthermore, in the HD knockin mice,
ER stress was found to occur prior to the formation of
amyloid intranuclear or cytoplasmic inclusions indicating
that it plays a critical role in the pathogenesis of HD
(Carnemolla et al. 2009). Postmortem analysis of patient
brains has found increased mRNA expression of the ER
stress-related genes BiP, CHOP and Herpud1 in HD
postmortem brain (Carnemolla et al. 2009).
Direct physical evidence for the association of KATs and
HDACs with critical regulatory elements within the ER stress
pathway is emerging. CHOP is an ER stress-inducible protein
which plays a critical role in regulating programmed cell
death. CHOP has recently been shown to directly associate
with the histone acetyltransferase p300, and inhibition of
HDACs prevents its degradation (Ohoka et al. 2007).
Chromatin immunoprecipitation analyses have shown that
ER stress regulators are regulated at the transcriptional level
via histone post-translational modifications (Donati et al.
2006). KAT3B has been shown to bind to the promoter for
the GRP78/BiP (Baumeister et al. 2005), whilst regulation of
the CHOP promoter involves a complex containing JDP2
and HDAC3 (Cherasse et al. 2008).
B lymphocyte-induced maturation protein-1 (BLIMP-1)
has been shown to be associated with cellular stress and is
rapidly upregulated during the UPR in some models
(Doody et al. 2006). This protein directly associates with
HDACs to repress transcription (Yu et al. 2000) and may
therefore indicate that BLIMP-1 may utilise HDACs to
downregulate important genes during ER stress.
Aggregation-prone proteins have been suggested to
overwhelm and impair the UPS in polyQ disorders, such
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dysfunction is a consistent feature of HD pathology with
impaired UPS in the synapses of HD mice (Bennett et al.
2007; Wang et al. 2008). ER stress has been shown to have
a general inhibitory effect on the UPS (Menendez-Benito et
al. 2005), which may explain the long-term gradual
accumulation of misfolded proteins in patients with HD.
Intriguingly in a neurodegenerative model for spinobulbar
muscular atrophy, autophagy was induced to compensate
for impaired UPS function in an HDAC6-dependent
manner (Pandey et al. 2007), whilst HDAC6 overexpres-
sion was sufficient to rescue the degeneration associated
with UPS dysfunction in vivo in an autophagy-dependent
manner (Pandey et al. 2007). Therefore, antagonists of
HDAC6 could potentially be used as an intervention to
induce compensatory autophagy in HD. Indeed inhibitors
targeting HDAC6 have been shown to alleviate the
microtubule transport- and release-defect phenotypes asso-
ciated with HD (Dompierre et al. 2007). HDAC6 would
therefore appear to be the critical regulator controlling
cellular response pathways to cytotoxic accumulation of
ubiquitinated protein aggregates and interacts with both
dynenin motors and misfolded proteins to form an active
transport system to transport misfolded proteins to the
aggresome (Kawaguchi et al. 2003). HDAC6 also plays a
role in regulating chaperone-mediated responses to cellular
stress. Ubiquitinated cellular aggregates impairing protea-
some activity triggers a HDAC6-dependent cell response
involving the induction of major cellular chaperones via
dissociation of a repressive HDAC6/heat shock factor 1/heat
shock protein 90 complex (Boyault et al. 2007). These and
other data showing that HDAC6 is a critical component of
environmentally induced stress granules (Kwon et al. 2007)
point to an essential role for HDAC6 as a cellular stress
surveillance factor, where it can be both a sensor of stressful
stimuli and an effector mediating and coordinating appropri-
ate cellular responses (Matthias et al. 2008).
Targeting HD using HDACi
From the previous sections, it could be argued that
targeting HDACs may be a way to target the neurode-
generative effects of HD. In the sections below, I shall
summarize the current literature on the effects of HDACi
in HD.
Neuroprotective effects of HDACi in models of HD
Sodium butyrate
In a cell culture model of HD, treatment of cells with
sodium butyrate caused the redistribution of huntingtin-
positive nuclear bodies (Kegel et al. 2002). The first
indications that HDAC inhibitors may prove useful in the
treatment of Huntington’s came from yeast and fly
models where treatments of Huntington’s disease models
were found arrest neurodegeneration or mitigated the
effects on affected gene promoters (Hughes et al. 2001;
Steffan et al. 2001). Sodium butyrate has also been
shown to ameliorate motor deficits in mouse HD model
(Ferrante et al. 2003)
Phenylbutyrate
Following on from these studies, it has since been shown
that the HDAC inhibitors PB can also ameliorate
Huntington motor deficits in mouse models (Gardian et
al. 2005). In vitro and in vivo models of Huntington’s
using ST14a/STHdh cells and R2/6 mice demonstrated a
marked histone H3 hypoacetylation in downregulated
genes, and treatment with HDAC inhibitors was found to
both reverse the mRNA abnormalities and led to histone
acetylation at the promoters of these genes (Sadri-Vakili et
al. 2007).
Currently, clinical trials are undergoing in relation to the
use of PB to treat HD. A phase II safety and tolerability trial
(NCT00212316) has been completed, and a serum analysis
has identified individual-specific patterns of ca. 20 metabo-
lites which could provide a means for the selection of subjects
for extended trials using this drug (Ebbel et al. 2010).
Valproic acid (Depakene® Depakote®)
High-dose valproate treatment of the transgenic mouse
N171-82Q model of HD significantly prolonged surviv-
al and ameliorated diminished spontaneous locomotor
activity, without exerting any noteworthy side effect on
their behaviour or the striatal dopamine content at the
dose administered (daily i.p., 100 mg/kg; Zadori et al.
2009). It must be noted that there has also been one
report linking valproic acid treatment with the develop-
ment of Pisa syndrome in a patient with HD (Salazar et
al. 2008).
Suberoylanilide hydroxamic acid (Vorinostat, Zolinza®)
Several studies have now shown that the first FDA
approved histone deacetylase inhibitor suberoylanilide
hydroxamic acid (SAHA; Zolinza®) has efficacy in
modulating the severity of HD models. The earliest such
study demonstrated that SAHA was able to ameliorate
motor deficits in a mouse model of Huntington’s disease
(Hockly et al. 2003).
SAHA is a pan-specific HDACi broadly inhibiting the
classes I, II and IV HDACs (Khan et al. 2008), but it has
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(Dokmanovic et al. 2007). SAHA can functionally decrease
the levels of HDAC7 in wild-type and the R6/2 transgenic
mouse model of HD (Benn et al. 2009). Despite this,
complete genetic loss of HDAC7 did not alleviate the
symptoms in HD models (Benn et al. 2009). As such,
HDAC7 would not appear to be the main target for the
therapeutic benefits of HDACi in HD models. SAHA has
also been shown to inhibit HDAC6. This deacetylase has a
special function in that it deacetylates microtubules in vitro
and in vivo (Hubbert et al. 2002). HDAC6 may therefore be
an important target in HD as levels of tubulin acetylation
were also found to be reduced in HD brains, whilst
treatment with the HDACi TSA ameliorated the phenotypic
effects of HD (Dompierre et al. 2007). Indeed, microtubule
dynamics associated with HDAC6 have also been shown to
be of broad potential interest in conditions of neuro-
degeneration. In Alzheimer’s disease, the protein tau has
been shown to inhibit HDAC6 resulting in increased
microtubule acetylation and prevents the induction of
autophagy by inhibiting proteasome function (Perez et al.
2009). Similarly, HDAC6 has also been shown to regulate
the cellular location of Parkin, a protein-ubiquitin E3 ligase
linked to Parkinson’s disease (Jiang et al. 2008).
Other HDACi
In the R6/2 transgenic mouse model of HD, a novel pimelic
diphenylamide HDAC inhibitor, HDACi 4b, significantly
improved motor performance, overall appearance and body
weight of symptomatic mice, with associated significant
attenuation of gross brain-size decline and striatal atrophy
(Thomas et al. 2008).
Potential use of HDACi to alleviate ER stress in HD
Data from in vitro studies are emerging demonstrating
the efficacy of the histone deacetylase inhibitor 4-
phenylbutyrate in relieving ER stress in cell line models
of cystic fibrosis (Rubenstein and Zeitlin 2000) and mutant
alpha1-ATZ liver disease (Burrows et al. 2000). Since these
initial observations, several studies have shown that 4-
phenylbutyrate may act as a chemical chaperone to relieve
ER stress induced in models of ischemia (Qi et al. 2004;
Vilatoba et al. 2005). Similar data have emerged for models
of cataract formation (Mulhern et al. 2007), Parkinson’s
disease (Kubota et al. 2006), retinitis pigmentosa (Bonapace
et al. 2004), glaucoma (Yam et al. 2007a) and reconfir-
mation of its ability to alleviate stress in cystic fibrosis
(Vij et al. 2006).
In diabetes, 4-phenylbutyrate has also been shown to
both relieve ER stress and restore glucose homeostasis in a
mouse model of type 2 diabetes. This occurs by the
restoration of systemic insulin sensitivity, resolution of
fatty liver disease and enhancement of insulin action in
liver, muscle and adipose tissues (Ozcan et al. 2006).
ER stress in liver-induced ischemia has been shown to be
ameliorated by treatments with 4-phenylbutyrate (Vilatoba et
al. 2005). This compound has also been shown to alleviate
oxidative stress-induced ER tress in cultured hepatocytes and
hepatoma cells (Hanada et al. 2007) and prevents ER stress-
mediated aggregate formation in a model of hereditary
haemochromatosis (de Almeida et al. 2007).
Valproate/valproic acid, another histone deacetylase
inhibitor, has also been shown to have potential in the
treatment of ER stress. Initial studies demonstrated that
treatment of cells with valproate caused the upregulation of
GRP78/BiP, a key ER-mediated chaperone (Wang et al.
1999). Subsequent studies confirmed that valproate could
increase the expression of additional important endoplasmic
reticulum stress proteins, GRP94 and calreticulin (Bown et
al. 2000; Chen et al. 2000; Shao et al. 2006). Valproate has
also been shown to protect against oxidative stress induced
protein damage and had provided neuroprotection in the
same model system (Wang et al. 2003; Shao et al. 2005;
Cui et al. 2007).
Using HDACi to potentially modulate chaperone activity
in HD
A plethora of studies have clearly shown that histone
deacetylase inhibitors can reactivate or alter gene
expression. However, histone deacetylases and histone
deacetylase inhibitors may also play important roles in
regulating chaperone expression and function. Obviously,
this has important implications in conditions such as HD
where aberrant misfolding of proteins can result in ER
stress (Vidal et al. 2011) and can be highlighted by the
fact that HDAC6 is recognised as a major regulator of
cellular responses aimed at counteracting the effects of
misfolded protein accumulation (Kovacs et al. 2005;
Boyault et al. 2006, 2007; Gao et al. 2007). Inhibition or
depletion of HDAC6 leads to induction of Hsp90
acetylation resulting in inhibition of its chaperone activity
(Fiskus et al. 2007;W a n ge ta l .2007b;S c r o g g i n se ta l .
2007; Edwards et al. 2007;B a l ie ta l .2005;K o n ge ta l .
2006). The class I HDACs (HDACs 1–3) have also been
shown to associate with the ATP-dependent chaperone
Hsp70, and this association enhances deacetylase catalytic
activity (Johnson et al. 2002).
Histone deacetylase inhibitors have emerged as
potential therapeutic agents in the relief of ER stress
induced in cell line models. Many of these studies have
utilised the chemical PB. For example, in a hepatocyte
cell line model of oxidative stress induced ER stress,
treatment of cells with PB was found to alleviate the ER
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of the benefits of PB as a chemical chaperone relieving
apoptosis and/or ER stress have been reported in models
of eye disease (Bonapace et al. 2004; Yam et al. 2007a),
d e f e c t i v et r a f f i c k i n go fn e p h r i ni nk i d n e y( L i ue ta l .2004),
rescue of protein trafficking in the lysosomal storage
disorder Fabry disease (Yam et al. 2007b), correction of
autodominant hypoparathyroidism-induced apoptosis
(Datta et al. 2007) and relief of ER stress-mediated
programmed cell death in Arabidopsis (Watanabe and
Lam 2007).
Other evidence for the potential of HDACi influencing
chaperone-like activities to relieve ER stress are emerging.
In cystic fibrosis models, phenylbutyrate can restore CFTR
trafficking and function (Zeitlin et al. 2002; Singh et al.
2006; Rubenstein and Zeitlin 1998, 2000; Rubenstein and
Lyons 2001; Rubenstein et al. 1997; Lim et al. 2004;
Kontopoulos et al. 2006; Choo-Kang and Zeitlin 2001),
through the induction of Hsp90 (Choo-Kang and Zeitlin
2001), and additional lung conditions for which beneficial
responses have been observed using HDACi as chemical
chaperones include respiratory distress syndrome (Cheong
et al. 2006) and emphysema (Burrows et al. 2000). HDACi
can also act as chemical chaperones in the liver. For
example, PB was used to protect liver cells from ER stress-
mediated apoptosis induced by liver ischemia (Vilatoba et
al. 2005), can enhance the cell-surface expression and
transport capacity of mutated bile salt export pumps
(Hayashi and Sugiyama 2007) and also reduce ER stress-
induced formation of Mallory bodies in hepatocytes
(Hanada et al. 2007).
However, it must be noted that within the neuronal setting,
initial studies on mood stabilizing drugs such as valproic acid
demonstrated increased expression of ER stress proteins in
cerebral cortex, hippocampus, neuronal and glial cells (Wang
etal. 1999;B o w ne ta l .2000;C h e ne ta l .2000; Corson et al.
2004;W a n ge ta l .2001;S h a oe ta l .2006).
Use of HDACi in patients with HD
Initial clinical trials testing the use of valproate in the
treatment of HD proved disappointing and did not show any
clinical benefit (Bachman et al. 1977;P e a r c ee ta l .1977;
Symington et al. 1978). More recent studies have, however,
demonstrated some benefit in HD patients either as specific
monotherapy (Saft et al. 2006) or as a combination therapy
with olanzipine (Grove et al. 2000).
Intensive pharmaceutical efforts have generated many
agents targeting histone deacetylases, and of these,
currently two have received FDA approval, SAHA/
Vorinostat (Zolinza) and FK228/Romidepsin (Istodax),
and both are currently licensed for the treatment of
cutaneous T cell lymphoma (Mann et al. 2007a; b;H y m e s
2010). Several histone deacetylase inhibitors which are
undergoing clinical trials have, or currently include, patients
with neurodegenerative diseases including HD, and as these
trials proceed, a better understanding of the potential side
effects and dose-limiting toxicities of these drugs will
emerge for patients with these conditions. For the most part,
the first generation inhibitors have shown well-tolerated
safety profiles (Lawless et al. 2009a).
A randomized, double-blind and placebo-controlled
phase I clinical trial by Elixir Pharmaceuticals of an orally
active, selective Sirt1 inhibitor SEN0014196 (6-chloro-
2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide), has been
initiated as a disease-modifying therapy in Huntington’s
disease, but results from this are not yet known.
Likewise, a phase I study examining the safety and
tolerability of phenylbutyrate in HD (PHEND-HD) has
recently been completed (Clinical Trials identifier—
NCT00212316). In this study, phenylbutyrate was found
to be both safe and well tolerated in early symptomatic
HD subjects taking 15 g daily, and levels leukocyte
histone acetylation were measurable, indicating that
HDAC inhibition was occurring in response to treatment
(Moser et al. 2008) A similar dose escalation/de-escala-
tion study using sodium phenylbutyrate in HD patients
agreed with the MTD of 15 g daily (Hogarth et al. 2007),
and at 12 g/daily was found to correct gene expression of a
12 gene biomarker set previously identified by this group
(Borovecki et al. 2005).
Future directions
Clearly, the potential utility of HDACi for the treatment
of HD exists. Several HDAC inhibitors have good safety/
tolerability profiles and are undergoing clinical trials in
neurodegenerative disease. It therefore seems imperative
that these drugs should continue to be tested for their
potential therapeutic role in patients afflicted with HD.
Further clinical trials are, however, required to demon-
strate their efficacy in alleviating the symptoms of this
disease, and indeed, it may be that HDACi may be more
effective in a combinatorial setting with other agents,
particularly for diseases such as HD. These and other
questions remain to be addressed, but it is clear that
these inhibitors may play important roles in both
targeting neurodegenerative conditions through their
activity on gene transcription and potentially through
additionally alleviating ER stress or modulating chaper-
one activity. Further experiments will, however, be
required to functionally address these possibilities.
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